Summit Therapeutics PLC Sponsored ADR Stock News

Summit Therapeutics Inc. (NASDAQ:SMMT ) Q3 2025 Earnings Call October 20, 2025 8:00 AM EDT Company Participants Dave Gancarz - Chief Business & Strategy Officer Howard (Jack) West Mahkam Zanganeh - Co-CEO, President & Director Manmeet Soni - COO, CFO & Director Urte Gayko - Chief Regulatory, Quality & Pharmacovigilance Officer Allen Yang - Chief Medical Officer Robert Duggan - Co-CEO & Executiv...

Summit Therapeutics is aggressively pursuing U.S. approval for ivonescimab in NSCLC, despite lacking statistically significant overall survival data. SMMT faces heightened financing risk due to increased trial enrollment and a limited cash runway, with dilution likely if partnerships don't materialize soon. The company's bold BLA strategy and expanded Phase 3 footprint increase binary risk, whi...

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the third quarter ended September 30, 2025. Planned BLA Submission for Ivonescimab in Q4 2025 Today, Summit announces that, based on the results of the HARMONi clinical trial, it plans to submit a Biol...

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced results from the Phase III HARMONi-6 trial, conducted in China and sponsored by our partner, Akeso, Inc. (HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented today as part of the Presi...

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III clinical development program of the novel, potential first-in-class investigational bispecific antibody, ivonescimab, into colorectal cancer (CRC) with the initiation of the global Phase III HARMONi-GI3 trial. Summit is starting a Phase III ...

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the market opens. The ESMO data relates to the planned disclosure of the HARMONi-6 clinical trial data. As a reminder, the Phase III HARMONi-6 trial, conducted in China and sponsored by our ...

Even in hindsight, it would have been difficult to predict Summit Therapeutics' (SMMT 2.88%) exceptional rise over the past three years. The company's shares have skyrocketed by more than 1,500% over this period.

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced the grant of inducement awards of options to purchase a collective total of up to 65,750 shares of common stock. Awards were made to eight new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Compan...